Innovative Palm-Sized Diagnostic Device Identifies Disease Markers in Under 45 Minutes Without Lab Equipment

A groundbreaking palm-sized device can detect disease markers in under 45 minutes without laboratory equipment, revolutionizing rapid diagnostics in various settings.
Scientists from the National University of Singapore have introduced NAPTUNE (Nucleic Acids and Protein biomarkers Testing via Ultra-sensitive Nucleases Escalation), a groundbreaking point-of-care diagnostic tool capable of detecting minute levels of disease-related genetic material, including nucleic acids and proteins, in less than 45 minutes. Remarkably, this device operates without the need for traditional laboratory equipment or complex procedures, making it ideal for rapid medical testing in diverse settings.
NAPTUNE simplifies molecular diagnostics by replacing conventional bulky amplification steps, such as PCR, with a two-enzyme cascade system. This system directly converts biological signals into easily detectable DNA fragments, significantly streamlining the diagnostic process. The core of the technology involves a two-stage enzymatic relay: the human DNA-repair enzyme APE1 recognizes engineered abasic sites in a DNA duplex, releasing DNA guides that activate the enzyme PfAgo. This second-stage enzyme cleaves specific probes, releasing fluorescent signals that increase proportionally with target concentration, achieving detection sensitivity down to the attomolar level—surpassing traditional methods.
The platform has been miniaturized into a portable, disposable setup controlled by a battery-powered heater and Bluetooth-enabled fluorescence reader weighing less than 200 grams. This mobile device allows real-time data streaming to a smartphone app, enabling on-site virus screening, rapid clinical diagnostics, and decentralized cancer monitoring.
The innovative approach addresses the limitations of traditional PCR and immunoassays, which often require extensive processing time, specialized equipment, and trained personnel. By harnessing naturally occurring nucleases in a tandem cascade, NAPTUNE offers rapid, highly sensitive detection suitable for low-resource environments.
Published in "Nature Communications" on February 4, 2025, the research was led by Assistant Professor Chunyi Hu, in collaboration with researchers from the University of Jinan and Lingang Laboratory in China. The team is currently validating NAPTUNE's effectiveness for tuberculosis detection and environmental surveillance, and plans to develop lyophilized reagent kits for tropical climates and expand detection modalities.
This portable, amplification-free diagnostic technology holds promise for transforming point-of-care testing, enabling immediate health assessments in community settings and resource-limited regions, paving the way for more accessible and faster disease detection.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Harnessing Digital Technology to Revolutionize Pediatric Nursing
Explore how digital technology, including AI, wearable sensors, and virtual tools, is transforming pediatric nursing by enhancing safety, personalization, and overall patient experience.
Innovative Test Enhances Quality Control in Allergy Treatments
A novel immunoassay developed by the Paul Ehrlich Institute allows precise measurement of allergoids in allergy medicines, improving quality control and standardization of allergy immunotherapy products.
Rivaroxaban Demonstrates Safety and Effectiveness for Long-Term Use in Children with Venous Thromboembolism
Recent long-term studies confirm that rivaroxaban is a safe and effective option for extended treatment of venous thromboembolism in children, offering a scientifically supported alternative to traditional therapies.
New Research Highlights the Critical Role of ADAM10 Protein in Retinal Disease Development
A groundbreaking study reveals the crucial role of ADAM10 protein in retinal neovascularization and offers promising new targets for treating vision-threatening retinal diseases.